keyword
MENU ▼
Read by QxMD icon Read
search

abiraterone response time in mCRPC

keyword
https://www.readbyqxmd.com/read/28700990/oncologic-response-and-hospitalization-rate-of-patients-receiving-cabazitaxel-in-the-fourth-line-and-beyond-in-castration-resistant-prostate-cancer-analysis-of-a-retrospective-cohort-and-a-structured-literature-review
#1
Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Arne Strauss, Thomas Stefan Worst, Philipp Nuhn, Christian Bolenz, Elmar Heinrich
BACKGROUND: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. PATIENTS AND METHODS: We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review...
July 13, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28655452/high-dose-abiraterone-acetate-in-men-with-castration-resistant-prostate-cancer
#2
Terence W Friedlander, Julie N Graff, Kreshnik Zejnullahu, Archana Anantharaman, Li Zhang, Rosa Paz, Gayatri Premasekharan, Carly Russell, Yong Huang, Won Kim, Rahul R Aggarwal, Amy M Lin, Lawrence Fong, Joshi J Alumkal, Tomasz M Beer, Nima Sharifi, Mohammad Alyamani, Ryan Dittamore, Eric J Small, Pamela L Paris, Charles J Ryan
BACKGROUND: Abiraterone acetate (AA) inhibits androgen biosynthesis and prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC) when combined with prednisone (P). Resistance to therapy remains incompletely understood. In this open-label, single-arm, multicenter phase II study we investigated the clinical benefit of increasing the dose of AA at the time of resistance to standard-dose therapy. PATIENTS AND METHODS: Eligible patients had progressive mCRPC and started AA 1000 mg daily and P 5 mg twice daily...
June 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28548924/comparing-the-clinical-efficacy-of-abiraterone-acetate-enzalutamide-and-orteronel-in-patients-with-metastatic-castration-resistant-prostate-cancer-by-performing-a-network-meta-analysis-of-eight-randomized-controlled-trials
#3
Minyong Kang, Chang Wook Jeong, Cheol Kwak, Ja Hyeon Ku, Hyeon Hoe Kim
Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable oncological outcomes. Here, we aimed to compare the efficacy of novel AR-targeted agents by performing a network meta-analysis of randomized controlled trials (RCTs). We included eight RCTs for men with mCRPC treated with one of the AR targeting agents: abiraterone acetate, enzalutamide, or orteronel...
May 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28314611/clinical-outcomes-from-androgen-signaling-directed-therapy-after-treatment-with-abiraterone-acetate-and-prednisone-in-patients-with-metastatic-castration-resistant-prostate-cancer-post-hoc-analysis-of-cou-aa-302
#4
Matthew R Smith, Fred Saad, Dana E Rathkopf, Peter F A Mulders, Johann S de Bono, Eric J Small, Neal D Shore, Karim Fizazi, Thian Kheoh, Jinhui Li, Peter De Porre, Mary B Todd, Margaret K Yu, Charles J Ryan
In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC. We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302...
March 14, 2017: European Urology
https://www.readbyqxmd.com/read/28213364/safety-and-antitumor-activity-of-apalutamide-arn-509-in-metastatic-castration-resistant-prostate-cancer-with-and-without-prior-abiraterone-acetate-and-prednisone
#5
Dana E Rathkopf, Emmanuel S Antonarakis, Neal D Shore, Ronald F Tutrone, Joshi J Alumkal, Charles J Ryan, Mansoor Saleh, Ralph J Hauke, Rajesh Bandekar, Edna Chow Maneval, Carla J de Boer, Margaret K Yu, Howard I Scher
Purpose: To evaluate the efficacy of apalutamide before or after treatment with abiraterone acetate and prednisone (AAP) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).Experimental Design: Two cohorts were studied: AAP-naïve and post-AAP patients who had received ≥6 months of AAP. Patients had progressive mCRPC per rising prostate-specific antigen (PSA) and/or imaging, without prior chemotherapy exposure. All received apalutamide 240 mg/day. Primary endpoint was ≥50% decline in 12-week PSA according to Prostate Cancer Working Group 2 criteria...
February 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28188090/independent-association-between-time-to-prostate-specific-antigen-psa-nadir-and-psa-progression-free-survival-in-patients-with-docetaxel-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-receiving-abiraterone-acetate-but-not-enzalutamide
#6
Hideaki Miyake, Takuto Hara, Keita Tamura, Takayuki Sugiyama, Hiroshi Furuse, Seiichiro Ozono, Masato Fujisawa
PURPOSE: The objective of this study was to compare the prognostic effect of time to prostate-specific antigen (PSA) nadir (TTPN) after treatment with abiraterone acetate (AA) and enzalutamide (Enz) in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer (mCRPC). METHODS: This study included a total of 297 consecutive patients with mCRPC, of whom 125 and 172 received AA and Enz, respectively, without previous treatment with docetaxel and subsequently achieved any degree of PSA reduction after the administration of either agent...
June 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28126272/prostate-specific-antigen-response-in-black-and-white-patients-treated-with-abiraterone-acetate-for-metastatic-castrate-resistant-prostate-cancer
#7
Sundhar Ramalingam, Michael S Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R Harrison, Andrew J Armstrong, Daniel J George, Tian Zhang
PURPOSE: Evidence suggests differences in androgen receptor AR signaling between black (B) and white (W) patients with prostate cancer, but pivotal trials of abiraterone acetate (AA) for patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled few black patients, a population with a higher mortality from prostate cancer. Our primary objective was to determine differences in response to AA between B and W patients. METHODS: We performed a retrospective case-control study of B vs...
June 2017: Urologic Oncology
https://www.readbyqxmd.com/read/27763885/duration-of-response-to-first-androgen-deprivation-therapy-time-to-castration-resistance-prostate-cancer-and-outcome-of-metastatic-castration-resistance-prostate-cancer-patients-treated-with-abiraterone-acetate
#8
Silvana Giacinti, Paolo Carlini, Michela Roberto, Maria Bassanelli, Lidia Strigari, Francesco Pavese, Anna M Aschelter, Alessandra Felici, Maurizio Valeriani, Francesco Cognetti, Paolo Marchetti
Abiraterone acetate (AA) demonstrated its efficacy in the treatment of patients with metastatic castration resistance prostate cancer (mCRPC) in predocetaxel and postdocetaxel setting. However, we learn from pivotal studies that forms of primary and acquired resistance to this drug exist. Patient selection becomes so crucial to optimize treatment results. Potential predictive biomarkers have been identified but are not yet validated. In this scenario, clinical features and disease characteristics may still be of value in selecting patients for different treatments...
January 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27544669/enzalutamide-as-a-fourth-or-fifth-line-treatment-option-for-metastatic-castration-resistant-prostate-cancer
#9
MULTICENTER STUDY
Sushil K Badrising, Vincent van der Noort, Paul Hamberg, Jules L L M Coenen, Maureen J Aarts, Inge M van Oort, Alfons J M van den Eertwegh, Maartje Los, H Pieter van den Berg, Hans Gelderblom, Suzan Vrijaldenhoven, Emile D Kerver, Theo van Voorthuizen, Igle J de Jong, John B Haanen, Andries M Bergman
OBJECTIVE: To evaluate the efficacy of enzalutamide (Enz) as fourth- or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. METHODS: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. RESULTS: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel...
2016: Oncology
https://www.readbyqxmd.com/read/27527643/comparing-sequencing-of-abiraterone-and-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-a-retrospective-study
#10
Benjamin L Maughan, Brandon Luber, Rosa Nadal, Emmanuel S Antonarakis
BACKGROUND: There are no validated clinical decision tools to aid optimal treatment selection in men with metastatic castration-resistant prostate cancer (mCRPC). Frequently, abiraterone and enzalutamide are used prior to chemotherapy in mCRPC, given the more favorable safety profiles. However, there is no published data on clinical outcomes regarding best sequencing of these two agents. METHODS: A retrospective analysis of consecutive mCRPC patients treated with enzalutamide and abiraterone at Johns Hopkins was conducted...
January 2017: Prostate
https://www.readbyqxmd.com/read/27504016/in-vitro-and-in-vivo-drug-drug-interaction-studies-to-assess-the-effect-of-abiraterone-acetate-abiraterone-and-metabolites-of-abiraterone-on-cyp2c8-activity
#11
Johan Monbaliu, Martha Gonzalez, Apexa Bernard, James Jiao, Carlo Sensenhauser, Jan Snoeys, Hans Stieltjes, Inneke Wynant, Johan W Smit, Caly Chien
Abiraterone acetate, the prodrug of the cytochrome P450 C17 inhibitor abiraterone, plus prednisone is approved for treatment of metastatic castration-resistant prostate cancer. We explored whether abiraterone interacts with drugs metabolized by CYP2C8, an enzyme responsible for the metabolism of many drugs. Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1...
October 2016: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/27450512/enzalutamide-in-patients-with-castration-resistant-prostate-cancer-progressing-after-docetaxel-retrospective-analysis-of-the-swiss-enzalutamide-named-patient-program
#12
Dimitrios Papazoglou, Luciano Wannesson, Dominik Berthold, Richard Cathomas, Silke Gillessen, Christian Rothermundt, Loretta Hasler, Ralph Winterhalder, Andreas Barth, Walter Mingrone, Catrina Uhlmann Nussbaum, Lukas von Rohr, Philippe von Burg, Mathias Schmid, Jürg Richner, Sylvia Baumann, Reto Kühne, Frank Stenner, Sacha I Rothschild
BACKGROUND: Enzalutamide is a second-generation androgen receptor (AR) inhibitor that binds to and blocks the AR with higher affinity than previously available AR inhibitors. High activity has been proven in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and in chemotherapy-naive patients with mCRPC. However, its activity in patients previously treated with other novel agents (for example, abiraterone and/or cabazitaxel), remains controversial...
June 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27436429/ar-v7-transcripts-in-whole-blood-rna-of-patients-with-metastatic-castration-resistant-prostate-cancer-correlate-with-response-to-abiraterone-acetate
#13
Tilman Todenhöfer, Arun Azad, Craig Stewart, Jian Gao, Bernhard J Eigl, Martin E Gleave, Anthony M Joshua, Peter C Black, Kim N Chi
PURPOSE: The expression of AR-V7 (androgen receptor splice variant) 7 in circulating tumor cells has been associated with resistance to abiraterone and enzalutamide in patients with metastatic castration resistant prostate cancer. We used a sensitive, whole blood reverse transcriptase-polymerase chain reaction assay that does not require circulating tumor cell enrichment to correlate outcomes of abiraterone with whole blood expression of AR-V7 and other prostate cancer associated transcripts...
January 2017: Journal of Urology
https://www.readbyqxmd.com/read/27409606/common-genetic-variation-in-cyp17a1-and-response-to-abiraterone-acetate-in-patients-with-metastatic-castration-resistant-prostate-cancer
#14
Moritz Binder, Ben Y Zhang, David W Hillman, Rhea Kohli, Tanvi Kohli, Adam Lee, Manish Kohli
Treatment with abiraterone acetate and prednisone (AA/P) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. We evaluated the genetic variation in CYP17A1 as predictive of response to AA/P. A prospective collection of germline DNA prior to AA/P initiation and follow-up of a mCRPC cohort was performed. Five common single-nucleotide polymorphisms (SNPs) in CYP17A1 identified using a haplotype-based tagging algorithm were genotyped. Clinical outcomes included biochemical response and time to biochemical progression on AA/P...
July 9, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27278777/association-of-early-psa-decline-and-time-to-psa-progression-in-abiraterone-acetate-treated-metastatic-castration-resistant-prostate-cancer-a-post-hoc-analysis-of-japanese-phase-2-trials
#15
Masahiko Nakayama, Hisanori Kobayashi, Tomihiro Takahara, Ryo Oyama, Keiichiro Imanaka, Kazutake Yoshizawa
BACKGROUND: Previous studies have demonstrated an association between prostate-specific antigen (PSA) kinetics and predictive value for treatment outcomes. Abiraterone acetate (AA) is a newly approved cytochrome-P450C17 inhibitor for treatment of metastatic castration-resistant prostate cancer (mCRPC), and few studies have evaluated PSA kinetics using AA so far. Results of a study evaluating PSA kinetics in the beginning of AA and enzalutamide responded chemotherapy-treated patients suggested different trends between the drugs...
June 8, 2016: BMC Urology
https://www.readbyqxmd.com/read/27212123/indirect-comparison-between-abiraterone-acetate-and-enzalutamide-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer-a-systematic-review
#16
REVIEW
Wei Zhang, Teng-Yun Wu, Qi Chen, Xiao-Lei Shi, Guang-An Xiao, Lin Zhao, Chuan-Liang Xu, Tie Zhou, Ying-Hao Sun
This study was designed to evaluate the efficacy, tolerability, and sequential administration of abiraterone acetate (AA) and enzalutamide (Enz) for metastatic castration-resistant prostate cancer (mCRPC). A literature search was performed with PubMed, Embase, and Web of Science databases to identify relevant studies. Reviewed literature included published phase III trials of AA or Enz in mCRPC and studies regarding their sequential administration. Given the difference in control arms in AA (active comparator) and Enz (true placebo) randomized phase III studies, indirect comparisons between AA and Enz in mCRPC showed no statistically significant difference in overall survival in prechemotherapy and postchemotherapy settings (HR: 0...
March 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/27150425/inherited-variants-in-sult1e1-and-response-to-abiraterone-acetate-by-men-with-metastatic-castration-refractory-prostate-cancer
#17
Neeraj Agarwal, Anitha B Alex, James M Farnham, Shiven Patel, David Gill, Tyler H Buckley, Robert A Stephenson, Lisa Cannon-Albright
PURPOSE: Germline variations in genes involved in androgen biosynthesis and metabolic pathways may predict the response to abiraterone acetate in men with metastatic, castration refractory prostate cancer. The variations may serve as prognostic and predictive biomarkers to allow for more individualized therapy. MATERIALS AND METHODS: We evaluated 832 single nucleotide polymorphisms from the OmniExpress genotyping platform (Illumina®) in the boundaries of 61 candidate genes reported to be involved in the androgen metabolic pathway...
October 2016: Journal of Urology
https://www.readbyqxmd.com/read/27148695/genomic-alterations-in-cell-free-dna-and-enzalutamide-resistance-in-castration-resistant-prostate-cancer
#18
Alexander W Wyatt, Arun A Azad, Stanislav V Volik, Matti Annala, Kevin Beja, Brian McConeghy, Anne Haegert, Evan W Warner, Fan Mo, Sonal Brahmbhatt, Robert Shukin, Stephane Le Bihan, Martin E Gleave, Matti Nykter, Colin C Collins, Kim N Chi
Importance: The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined. Consequently, there is an urgent need for practical biomarkers to guide therapy selection and elucidate resistance. Although tissue biopsies are impractical to perform routinely in the majority of patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimally invasive method to explore tumor characteristics...
December 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27015255/budget-impact-of-enzalutamide-for-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer
#19
Cat N Bui, Ken O'Day, Scott Flanders, Nina Oestreicher, Peter Francis, Linda Posta, Breanna Popelar, Hong Tang, Mark Balk
BACKGROUND: Prostate cancer is expected to account for approximately one quarter of all new diagnoses of cancer in American men in 2015. The cost of prostate cancer care is expected to reach $15.1 billion by the year 2020, up from $11.9 billion in 2010. Given the high burden of prostate cancer, health care payers are interested in quantifying the potential budget impact of new therapies. OBJECTIVE: To estimate the budget impact of enzalutamide for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) from a U...
February 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27001043/abiraterone-acetate-in-metastatic-castration-resistant-prostate-cancer-the-unanticipated-real-world-clinical-experience
#20
MULTICENTER STUDY
Darren M C Poon, Kuen Chan, S H Lee, T W Chan, Henry Sze, Eric K C Lee, Daisy Lam, Michelle F T Chan
BACKGROUND: There is much interest in confirming whether the efficacy of abiraterone acetate (AA) demonstrated within the trial setting is reproducible in routine clinical practice. We report the clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with AA in real-life clinical practice. METHODS: The clinical records of mCRPC patients treated with AA from all 6 public oncology centers in Hong Kong between August 2011 and December 2014 were reviewed...
March 22, 2016: BMC Urology
keyword
keyword
102816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"